Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a strong-buy rating in a research note published on Saturday morning.

A number of other research analysts have also weighed in on the company. Zacks Research lowered Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Finally, Stifel Nicolaus upped their target price on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research note on Friday, December 19th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $62.17.

Supernus Pharmaceuticals Price Performance

NASDAQ:SUPN opened at $55.09 on Friday. The firm’s 50-day moving average price is $50.76 and its 200-day moving average price is $48.48. The company has a market capitalization of $3.16 billion, a PE ratio of -81.01, a P/E/G ratio of 1.70 and a beta of 0.70. Supernus Pharmaceuticals has a 1-year low of $29.16 and a 1-year high of $59.68.

Insider Activity at Supernus Pharmaceuticals

In other news, SVP Frank Mottola sold 20,000 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $50.41, for a total transaction of $1,008,200.00. Following the transaction, the senior vice president directly owned 15,496 shares of the company’s stock, valued at $781,153.36. This represents a 56.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Padmanabh P. Bhatt sold 710 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $44.44, for a total value of $31,552.40. Following the completion of the transaction, the vice president owned 14,508 shares in the company, valued at approximately $644,735.52. This trade represents a 4.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 25,185 shares of company stock worth $1,268,022 over the last quarter. Company insiders own 8.80% of the company’s stock.

Institutional Trading of Supernus Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Royal Bank of Canada grew its stake in shares of Supernus Pharmaceuticals by 68.1% during the 1st quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock valued at $382,000 after purchasing an additional 4,729 shares during the period. AQR Capital Management LLC increased its holdings in Supernus Pharmaceuticals by 35.2% during the first quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock valued at $2,791,000 after buying an additional 22,182 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Supernus Pharmaceuticals by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock worth $978,000 after acquiring an additional 1,297 shares during the period. Millennium Management LLC boosted its stake in shares of Supernus Pharmaceuticals by 370.5% during the 1st quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock worth $4,695,000 after acquiring an additional 112,886 shares during the last quarter. Finally, Empowered Funds LLC grew its position in shares of Supernus Pharmaceuticals by 16.0% during the 1st quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock valued at $1,573,000 after acquiring an additional 6,619 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.